Information Provided By:
Fly News Breaks for February 14, 2019
ISRG, JNJ
Feb 14, 2019 | 08:25 EDT
Credit Suisse analyst Vamil Divan says the Auris Health deal brings to Johnson & Johnson (JNJ) an attractive collection of robotic surgery assets, including 3 FDA-cleared robotic systems, a pipeline of additional applications and technologies, as well as significant robotics IP from both Auris and Hansen. Auris also brings substantial R&D and commercialization expertise related to robotic surgery systems, not least of which is Fred Moll - founder of Intuitive Surgical (ISRG) -, who is expected to remain with the program for the next 2-3 years, if not longer, the analyst adds. Divan reiterates an Outperform rating and $151 target on Johnson & Johnson, and views the Auris deal as an incremental near-term positive, with potentially significant long-term positive impact as the company's robotic surgery strategy unfolds.
News For JNJ;ISRG From the Last 2 Days
JNJ
Mar 28, 2024 | 16:23 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
JNJ
Mar 28, 2024 | 13:57 EDT
Johnson & Johnson will pay $75M to settle a consumer protection lawsuit filed by Mississippi over the company's talc-based baby powder, according to people familiar with the matter, resolving litigation in which the state had sought as much as $6B, Bloomberg News' Jef Feeley reports. The pact comes as lawyers for the state and J&J were gearing up for a non-jury trial next month in Jackson, Mississippi, said the people. Mississippi was one of only two states to file suit over J&J's marketing of its baby powder, the author notes. Reference Link